Author: Hu, Zhiqiang; Xing, Yaling; Qian, Yuanyu; Chen, Xiaojuan; Tu, Jian; Ren, Lening; Wang, Kai; Chen, Zhongbin
Title: Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist Document date: 2012_10_26
ID: 6fp8nly0_27
Snippet: Activation of the TLR5-NF-κB signaling pathway has emerged as an effective mechanism in developing radiation protection compounds [17] [18] [19] [20] . NF-κB is an important nuclear transcriptional regulation factor, which participates in the transcription regulation of diverse genes, and actively contributes to immune response and cell cycle activity. Investigation of the NF-κB pathway has unveiled its involvement in certain medical condition.....
Document: Activation of the TLR5-NF-κB signaling pathway has emerged as an effective mechanism in developing radiation protection compounds [17] [18] [19] [20] . NF-κB is an important nuclear transcriptional regulation factor, which participates in the transcription regulation of diverse genes, and actively contributes to immune response and cell cycle activity. Investigation of the NF-κB pathway has unveiled its involvement in certain medical conditions, such as cardiovascular diseases, neurological disorders, immune dysfunctions, tumors and radiation-induced injury [17] [18] [19] [20] . Establishment of an effective cell-based model for screening agonists of the human TLR5-mediated NF-κB pathway will help to identify compounds with greater specific action on the pathway, without side-effects on other signaling networks, to achieve pharmacological effects. For this purpose, we cloned the human TLR5 gene and created pcDNA3.1-V5/HisB-hTLR5 plasmid for use in the present study. Our human TLR5 cell model is more suitable for screening the human type TLR5-mediated NF-kB activity aiming for human therapeutic application than the early commercial murine TLR5 plasmid model used in previous studies [13] .
Search related documents:
Co phrase search for related documents- cardiovascular disease and cell model: 1, 2, 3, 4
- cardiovascular disease and effective mechanism: 1
- cardiovascular disease and immune dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- cardiovascular disease and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cardiovascular disease and medical condition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- cardiovascular disease and neurological disorder: 1, 2
- cardiovascular disease and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
- cardiovascular disease and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cardiovascular disease and specific action: 1
- cardiovascular disease and therapeutic application: 1, 2
- cardiovascular disease and transcription regulation: 1, 2
- cell base and immune response: 1, 2, 3
- cell base and present study: 1
- cell cycle and diverse gene: 1
- cell cycle and effective mechanism: 1, 2
- cell cycle and human type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- cell cycle and immune dysfunction: 1
- cell cycle and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- cell cycle and medical condition: 1
Co phrase search for related documents, hyperlinks ordered by date